Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Breast Neoplasms 2Salivary Gland Neoplasms 1Neoadjuvant Therapy 1

Interventions

Trastuzumab 3trastuzumab deruxtecan 2sacituzumab govitecan 2pertuzumab 2pembrolizumab 2Magnetic Resonance Spectroscopy 2Goserelin 2Carboplatin 2Biopsy 2Ado-Trastuzumab Emtansine 2zanidatamab 1trastuzumab biosimilar HLX02 1spartalizumab 1pyrotinib 1enfortumab vedotin 1camrelizumab 1bicalutamide 1apatinib 1abiraterone 1Tablets 1Specimen Handling 1Radiation 1Poly(ADP-ribose) Polymerase Inhibitors 1Platinum 1PF-05280014 1Ontruzant 1Ogivri 1Observation 1Maytansine 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Salivary Gland Neoplasms × Poly(ADP-ribose) Polymerase Inhibitors × Clear all
NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Peking Union Medical College

Phase 2 Recruiting
39 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡